✦ LIBER ✦

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial

✍ Scribed by Adriano Lazzarin; Thomas Campbell; Bonaventura Clotet; Margaret Johnson; Christine Katlama; Arend Moll; William Towner; Benoit Trottier; Monika Peeters; Johan Vingerhoets; Goedele de Smedt; Benny Baeten; Greet Beets; Rekha Sinha; Brian Woodfall

Book ID: 117301430
Publisher: The Lancet
Year: 2007
Tongue: English
Weight: 193 KB
Volume: 370
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(07)61048-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of TMC125 (etravirin

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial

✍ José Valdez Madruga; Pedro Cahn; Beatriz Grinsztejn; Richard Haubrich; Jacob Lal 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 193 KB

Safety and efficacy of zinc supplementat

Safety and efficacy of zinc supplementation for children with HIV-1 infection in South Africa: a randomised double-blind placebo-controlled trial

✍ Raziya Bobat; Hoosen Coovadia; Cindy Stephen; Kimesh L Naidoo; Neil McKerrow; Ro 📂 Article 📅 2005 🏛 The Lancet 🌐 English ⚖ 89 KB

Efficacy and safety of ustekinumab, a hu

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

✍ Craig L Leonardi; Alexa B Kimball; Kim A Papp; Newman Yeilding; Cynthia Guzzo; Y 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 222 KB

Efficacy and safety of ustekinumab, a hu

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

✍ Kim A Papp; Richard G Langley; Mark Lebwohl; Gerald G Krueger; Philippe Szapary; 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 295 KB

Efficacy and safety of darunavir-ritonav

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

✍ Bonaventura Clotet; Nicholas Bellos; Jean-Michel Molina; David Cooper; Jean-Chri 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 180 KB

Safety and efficacy of raltegravir-based

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

✍ Jeffrey L Lennox; Edwin DeJesus; Adriano Lazzarin; Richard B Pollard; Jose Valde 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 248 KB